Contact X-Ray Brachytherapy for Rectal Cancer

  • Arthur Sun MyintEmail author
  • Jean-Pierre Gerard
  • Robert J. Myerson


Over the past century, surgery has been the mainstay of rectal cancer management and will remain so for the foreseeable future. However, surgical mortality and morbidity is high, especially for the elderly patients. The population is ageing globally, the effect being more pronounced in Western countries. It is important to avoid extirpative surgery, especially in elderly patients, to deter surgical harm. National bowel cancer screening programmes around the world have helped to diagnose rectal cancer in its early stages. It is important to treat the early stages of the disease differently from the more advanced stages. Most protocols are bias heavily towards surgical management for rectal tumors. National and international consensus guidelines do not take into consideration the advancing age of the general population and recommend surgery as the gold standard of care. There is an urgent need to consider alternative treatment options that avoid extirpative surgery and stoma in the early stages of rectal cancer in the elderly.


Contact X-rays Brachytherapy Papillon Early rectal cancer Dose response High dose superficial X-rays Complete clinical response 


  1. 1.
    Atkins WS, Cook CF, Cruzik J, et al. Single flexible sigmoidoscopy screening to prevent colorectal cancer: baseline findings of a UK multicenter randomised trial. Lancet. 2010;13:1291–300.Google Scholar
  2. 2.
    Patel UB, Taylor F, Blomqvist L, et al. Magnetic resonance imaging – detected tumour response for locally advanced rectal cancer predicts survival outcomes: MERCURY experience. J Clin Oncol. 2011;29:3753–60.PubMedCrossRefGoogle Scholar
  3. 3.
    Brown G, Daniels I, Richardson C, et al. Techniques and trouble shooting in high spatial resolution thin slice MRI for rectal cancer. Br J Radiol. 2005;78:245–51.PubMedCrossRefGoogle Scholar
  4. 4.
    Ngan SY, Burmeister B, Fisher RJ, et al. Randomized trial of short course radiotherapy versus long course chemoradiotherapy comparing rates of local recurrence in patients with T3 rectal cancer. Trans-Tasman Radiation Oncology Group (TROG) Trial 01.04. J Clin Oncol. 2012;30:3827–33.PubMedCrossRefGoogle Scholar
  5. 5.
    Sun Myint A, Whitmarsh K, Perkins K, et al. A preliminary report on toxicity of contact radiotherapy in first 100 patients treated by the new RT50 Papillon machine. Colorectal Dis. 2013;15:Abstract P081.Google Scholar
  6. 6.
    Habr-Gama A, Perez RO, Wynn G, et al. Complete response after neo adjuvant chemoradiation for distal rectal cancer: characterisation of clinical and endoscopic findings for standardization. Dis Colon Rectum. 2010;53:1692–8.PubMedCrossRefGoogle Scholar
  7. 7.
    Hershman MJ, Sun Myint A. Salvage surgery after inadequate combined local treatment for early rectal cancer. Clinical Oncology. 2007;19:720–3.PubMedCrossRefGoogle Scholar
  8. 8.
    Smith F, Change KH, Sheahan K, et al. The surgical significance of residual mucosal abnormalities in rectal cancer following neoadjuvant chemoradiotherapy. Br J Surg. 2012;99:993–1001.PubMedCrossRefGoogle Scholar
  9. 9.
    Chaoul M, Wachsmann F. Die Nahbestrahlung. Stuttgart: Thieme; 1953.Google Scholar
  10. 10.
    Lamarque PL, Gros CG. La radotherapie de contact des cancers du rectum. J Radiol Electrol. 1946;27:333–46.Google Scholar
  11. 11.
    Papillon J. Present status of radiation therapy in conservative management of rectal cancer. Radiother Oncol. 1990;17:275–83.PubMedCrossRefGoogle Scholar
  12. 12.
    Sischy B. The role of endocavitary irradiation for limited lesion of the rectum. Int J Colorectal Dis. 1991;6:91–4.PubMedCrossRefGoogle Scholar
  13. 13.
    Myerson RJ, Hunt SR. Conservative alternatives to extirpative surgery for rectal cancer. Clin Oncol. 2007;19:682–6.CrossRefGoogle Scholar
  14. 14.
    Gerard JP, Ayazac L, Coquard R, et al. Endocavitary irradiation for early rectal carcinoma T1 (T2). A series of 101 patients treated with the Papillion’s technique. Int J Radiat Oncol Biol Phys. 1996;34(4):775–83.PubMedCrossRefGoogle Scholar
  15. 15.
    Gerard JP, Chapet O, Orthalan C, et al. French experience with contact X-ray endocavitary radiation for early rectal cancer. Clin Oncol. 2007;19:661–73.CrossRefGoogle Scholar
  16. 16.
    Gerard JP, Chapet O, Nemoz C, et al. Improved sphincter preservation in low rectal cancer with high dose radiation. J Clin Oncol. 2004;22:2404–9.PubMedCrossRefGoogle Scholar
  17. 17.
    Ortholan O, Chapet O, Gerard JP, et al. Correlation in rectal cancer between clinical tumour responses after neoadjuvant radiotherapy and sphincter or organ preservation. Int J Radiat Oncol Biol Phys. 2012;83(2):165–71.Google Scholar
  18. 18.
    Gerard JP, Ortholan C, Benezery K, et al. Contact X-ray radiotherapy for rectal cancer: experience in Centre Antoine-Lacassagne, Nice 2002–2006. Int J Radiat Oncol Biol Phys. 2008;72(3):665–70.PubMedCrossRefGoogle Scholar
  19. 19.
    Gerard JP, Sun Myint A, Croce O, et al. Renaissance of contact X-ray therapy for treating rectal cancer. Expert Rev Med Devices. 2011;8(4):483–92.PubMedCrossRefGoogle Scholar
  20. 20.
    Hershman MJ, Sun Myint A, Makin C. Multimodality approach in curative local treatment of early rectal carcinomas. Colorectal Dis. 2003;5:445–50.PubMedCrossRefGoogle Scholar
  21. 21.
    Sun Myint A, Grieve RJ, McDonald AC, et al. Combined modality treatment of early rectal cancer – the UK experience. Clin Oncol. 2007;19:674–81.CrossRefGoogle Scholar
  22. 22.
    Habr-Gama A, Gama-Rorigues J, Sao Juliao GP, et al. Local recurrence after complete clinical response and watch and wait in rectal cancer after neoadjuvant chemoradiation: impact of salvage therapy on local disease control. Int J Radiat Oncol Biol Phys. 2012;88(4):822–8.CrossRefGoogle Scholar
  23. 23.
    Mass M, Beets-Tan R, Lambregts DMJ, et al. Wait and see policy for clinical complete response after chemoradiation for rectal cancer. J Clin Oncol. 2011;29:4633–40.CrossRefGoogle Scholar
  24. 24.
    Wiltshire K, Brierley J, Swallow C, et al. Preoperative radiation with concurrent chemotherapy for resectable rectal cancer; effect of dose escalation on pathological complete response, local recurrence free survival and disease free survival. Int J Radiat Oncol Biol Phys. 2004;60(1):Abstract 1061.Google Scholar
  25. 25.
    Jakobsen AKM, PlØen J, Vuong T, et al. The dose effect relationship in preoperative chemoradiotherapy of locally advanced rectal cancer: a randomised trial comparing two radiation doses. Int J Radiat Oncol Biol Phys. 2012;84(4):949–54.PubMedCrossRefGoogle Scholar
  26. 26.
    Appelt AL, PlØen J, Vogelius IV, et al. Radiation dose response model for locally advanced rectal cancer after preoperative chemoradiation therapy. Int J Radiat Oncol Biol Phys. 2013;85(1):74–80.PubMedCentralPubMedCrossRefGoogle Scholar
  27. 27.
    Bosset JF, Collette L, Calais G, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006;355:1114–23.PubMedCrossRefGoogle Scholar
  28. 28.
    Macfarlane JK, Ryall RDH, Heald RJ. Mesorectal excision for rectal cancer. Lancet. 1993;341:457–60.PubMedCrossRefGoogle Scholar
  29. 29.
    Maas M, Nelemans PJ, Valentini V, et al. Long term outcome in patients with pathological complete response after chemoradiation for rectal cancer. A pool analysis of individual patient data. Lancet Oncol. 2010;11:835–44.PubMedCrossRefGoogle Scholar
  30. 30.
    Rutten H, den Dulk M, Lemmens VE, Van de Velde CJ, et al. Controversies of total mesorectal excision for rectal cancer in elderly patients. Lancet Oncol. 2008;9(5):491–501.CrossRefGoogle Scholar
  31. 31.
    Bach S, Hill J, Monson J, et al. A predictive model for local recurrence following transanal endoscopic microsurgery for rectal cancer. Br J Surg. 2009;96:280–90.PubMedCrossRefGoogle Scholar
  32. 32.
    Morris E, Quirk P, Thomas JD. Unacceptable variation in abdomino-perineal excision rates for rectal cancer: time to intervene? Gut. 2008;57(12):1690–7.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London 2015

Authors and Affiliations

  • Arthur Sun Myint
    • 1
    Email author
  • Jean-Pierre Gerard
    • 2
  • Robert J. Myerson
    • 3
  1. 1.OncologyClatterbridge Cancer Centre, University of LiverpoolWirralUK
  2. 2.Service de RadiothérapieCentre Antoine-LacassagneNiceFrance
  3. 3.Department of Radiation OncologyWashington University School of MedicineSt.LouisUSA

Personalised recommendations